Great to convene another closed-door session with investors, operators, and strategics across Singapore, China, Korea, Taiwan, the Philippines, and the US — a reminder that biotech today is inherently global, even at the earliest stages.

A few consistent themes emerged across speakers and discussions:

1️⃣ Start with the right asset (Dr. Keting Chu)
Strong science is table stakes. What matters is whether the asset addresses a real unmet medical need — and how clearly that translates into investor value. Trends come and go, but the right asset compounds.

2️⃣ The real opportunity lies in the “valley of death” (Dr. Stephen Phua)
As global capital shifts toward later-stage, de-risked assets, a gap is emerging in early development — where innovation is created, but outcomes are more volatile.

This creates a window for Asia, including China, to step in and capture value at this critical stage.

3️⃣ Bridging ecosystems is the real opportunity (Prof. SZE-WEE TAN)
Asia has no shortage of innovation or capital — but translating this into globally competitive biotech companies remains the challenge.

One pathway discussed: originating IP in China and structuring it through Singapore for translational development and global pathways.

4️⃣ Biotech is cross-border by default
From clinical trials to regulatory strategy to commercialization, success increasingly depends on navigating multiple geographies effectively.

Across investors, founders, and strategics, the message was consistent:

👉 The next generation of Asian biotech will be built at the intersection of strong assets, disciplined execution, and cross-border alignment of capital and strategy.

Appreciate everyone who joined and contributed to a thoughtful and candid discussion.